Clinical Trials
18 trialsNCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT05889871 2023-06-05
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Fudan University
Phase 3 Unknown
NCT03048877 2023-04-12
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05049681 2021-09-20
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The First Affiliated Hospital of Zhengzhou University
Phase 3 Unknown
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT04296370 2020-08-10
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04203485 2020-05-08
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04000295 2019-10-08
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03889626 2019-03-26
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
Fudan University
Phase 3 Unknown
NCT03651219 2018-08-29
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
Beijing Chest Hospital
Phase 3 Unknown
NCT03598348 2018-07-26
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 3 Unknown
NCT03355612 2017-11-28
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03100955 2017-04-04
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
Qingdao University
Phase 3 Unknown
NCT02332512 2017-02-24
ANSWER
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02537171 2016-08-02
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 3 Unknown
NCT02824458 2016-07-07
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Sun Yat-sen University
Phase 3 Unknown
NCT01287962 2013-12-09
Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Unknown